Trial Details
COMPLETEDBasic Information
| Clinical ID | c331 |
|---|---|
| Identifier | NCT02539368 |
| Trial Title | Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Inflammatory Bowel Diseases|Ulcerative Colitis|Crohn's Disease |
| Interventions | DRUG: CT-P13|DRUG: Remicade |
Participant Information
| Sponsor | Pfizer |
|---|---|
| City | Leuven |
| Country/Region | Belgium |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | OBSERVATIONAL |
|---|---|
| Phase | - |
Time Information
| Start Date | 2015-04-22 |
|---|---|
| Primary Completion Date | 2018-10-31 |
| Completion Date | 2018-10-31 |